Form 6-K LakeShore Biopharma Co., For: Jun 24

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2026

 

Commission file number: 001-41598

 

 

LAKESHORE BIOPHARMA CO., LTD

(Exact name of registrant as specified in its charter)

 

 

Building No. 2, 38 Yongda Road

Daxing Biomedical Industry Park

Daxing District, Beijing, PRC

Tel: 010-89202086

(Address of Principal Executive Offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒          Form 40-F  ☐

 

 

 

EXHIBITS

 

Exhibit No.		Description
99.1		Press Release - LakeShore Biopharma Announces Completion of Going Private Transaction

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	LakeShore Biopharma Co., Ltd
	By:	/s/ Rachel Yu
	Name:	Rachel Yu
	Title:	Director and Chief Financial Officer

 

Date: June 24, 2026

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE - LAKESHORE BIOPHARMA ANNOUNCES COMPLETION OF GOING PRIVATE TRANSACTION

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Arvulonikanz Reviews: Is Arvulonikanz AI Trading Platform Worth It?
• Clarivate Selected by Abes to Modernize French National Academic Library System
• Court Approves Option to Acquire the Renard Mine Site